INTEGRA LIFESCIENCES HOLDINGS CORP — fact timeline

INTEGRA LIFESCIENCES HOLDINGS CORP reported the first quarter ending March 31, 2026 results: revenue $391.9 million, net income $(4.6) million, EPS $(0.06) per diluted share. Guidance raised.

“Total reported revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 55.4%, compared to 50.8% in the first quarter of 2025. Adjusted gross margin was 64.1%, compared to 62.2% in the prior year. Adjusted EBITDA for the first quarter of 2026 was $76.2 million, or 19.4% of revenue, compared to $63.6 million, or 16.6% of revenue, in the prior year. The Company reported a GAAP net loss of $(4.6) million, or $(0.06) per diluted share, in the first quarter of 2026, compared to GAAP net loss of $(25.3) million, or $(0.33) per diluted share, in the prior year.”

Mojdeh Poul departed as Director at INTEGRA LIFESCIENCES HOLDINGS CORP.

“Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").”

Mojdeh Poul departed as President and Chief Executive Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").”

Stuart M. Essig was appointed as President and Chief Executive Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“On May 5, 2026, Integra LifeSciences Holdings Corporation (the "Company") announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026 (the "Start Date").”

INTEGRA LIFESCIENCES HOLDINGS CORP entered into April 2026 Amendments with PNC Bank, National Association valued at amendment to $150 million accounts receivable securitization facility (effective 2026-04-10).

“On April 10, 2026, (i) the Borrower and ILS Sales entered into Amendment No. 8 to Receivables Financing Agreement (the “RFA Amendment”), by and among the Borrower, ILS Sales, as Servicer, PNC, as Administrative Agent and Committed Lender, The Bank of Nova Scotia, as Committed Lender and Group Agent, PNC Capital Markets LLC, as Structuring Agent, and certain lenders and group agents that are parties thereto from time to time and (ii) the Borrower and ILS Sales entered into Amendment No. 1 to Purchase and Sale Agreement(the “PSA Amendment,” and together with the RFA Amendment, the “April 2026 Amendments”), by and between the Borrower, as Buyer and ILS Sales, as Servicer, and acknowledged and agreed by PNC, as Administrative Agent.”

Mojdeh Poul was appointed as President and Chief Executive Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“On November 4, 2024, Integra LifeSciences Holdings Corporation (the “Company”) announced the appointment of Mojdeh Poul to serve as its President and Chief Executive Officer.”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Approval of the Plan Amendment at the 2024-05-09 meeting.

“The stockholders approved the Plan Amendment, by the votes set forth below:”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Amendment to Amended and Restated Certificate of Incorporation to limit liability of certain officers at the 2024-05-09 meeting.

“The stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to limit the liability of certain officers of the Company as permitted by recent amendments to the General Corporation Law of the State of Delaware, by the votes set forth below:”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Advisory (non-binding) approval of executive compensation at the 2024-05-09 meeting.

“The stockholders approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers, by the votes set forth below.”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2024 at the 2024-05-09 meeting.

“The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2024 fiscal year, by the votes set forth below.”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Election of Directors at the 2024-05-09 meeting.

“All of the nominees for director of the Board of Directors (the “Board”) of the Company were elected to serve until the Company’s 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth below.”

INTEGRA LIFESCIENCES HOLDINGS CORP reported the quarter ended March 31, 2024 results: revenue $368.9 million, net income $(3.3) million, EPS $(0.04) per diluted share. Guidance raised.

“Total reported revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Organic growth excluding Boston was 1.6%. Revenue exceeded the outlook the Company provided in February. The Company reported GAAP gross margin of 56.1%, compared to 61.1% in the first quarter of 2023. Adjusted gross margin was 64.4%, compared to 67.3% in the prior year. Adjusted EBITDA for the first quarter of 2024 was $71.8 million, or 19.5% of revenue, compared to $92.3 million, or 24.2% of revenue, in the prior year. The Company reported a GAAP net loss of $(3.3) million, or $(0.04) per diluted share, in the first quarter of 2024, compared to a GAAP net income of $24.2 million, or $0.29 per diluted share, in the prior year.”